☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Share this
PS Admin
Jun 20, 2024
Clinical Trials
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Click here
to read the full press release
Comments
Fill this Details
×
Name
Email
Company Name
Thank you for download PDF
Submit
Related News/Articles
Tubulis Reports the US FDA’s Fast Track Designation of TUB-040 to Treat Ovarian Cancer
June 28, 2024
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-aa
June 20, 2024
PharmaShots Weekly Snapshots (April 14, 2025 – April 18, 2025)
April 18, 2025
BigHat Biosciences Collaborates with Eli Lilly to Advance AI-Driven Antibody Therapeutics
April 18, 2025
Driving Precision Medicine Education: A Star Wars-Themed Talk on a Needed Approach
April 18, 2025
Streamlining Pharmaceutical Claims: Kate Flathers from Kalderos in a Stimulating Conversation with PharmaShots
April 17, 2025
Merck Signs a ~$493M Deal with Cyprumed to Develop Oral Peptide Therapeutics
April 15, 2025
CXO Talks: Ali Jannati from Linus Health in a Stimulating Dialogue Exchange with PharmaShots
April 14, 2025
PharmaShots Magazine-April-2025 Edition
April 10, 2025
Scientist.com Launches Clinical Labs Navigator to Improve Clinical Trial Operations
April 9, 2025
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
×
Email
First Name
Last Name
Company Name
Area/Designation
Daily Newsletter
Weekly Newsletter
Stay Connected
LinkedIn
Twitter
Facebook
instagram
Youtube
Join the PharmaShots family of 12000+ subscribers
Newsletter
Subscribe Now
I accept the
Terms and Conditions
X
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
Subscribe
Modal title
×
Modal body text goes here.
